強心剤の世界市場

強心剤の世界市場は2030年までに30億米ドルに到達

2024年に10億米ドルと推定される強心剤の世界市場は、2024年から2030年にかけてCAGR 19.4%で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるジギタリス配糖体は、CAGR 21.6%を記録し、分析期間終了時には12億米ドルに達すると予測されます。ホスホジエステラーゼ阻害剤セグメントの成長率は、分析期間中CAGR 20.5%と推定されます。

米国市場は2億8,470万米ドルと推定、中国はCAGR26.5%で成長すると予測

米国の強心剤市場は、2024年に2億8,470万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億2,080万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは26.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に15.3%と17.5%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約16.3%で成長すると予測されています。

世界の強心剤市場- 主要動向と促進要因のまとめ

強心剤が多様な医療現場における急性心不全および慢性心不全の管理に不可欠なのはなぜか？

強心剤-主に心筋収縮力を増強するために使用される-は、心不全、心原性ショック、特定の不整脈の薬理学的管理の要であり続けています。ジギタリス配糖体（例：ジゴキシン），ホスホジエステラーゼ阻害薬（例：ミルリノン），アドレナリン作動薬（例：ドブタミン）を含むこれらの薬剤は，駆出率が低下したり心拍出量が低下した場合に重要な血行動態のサポートを提供します。新規の心不全治療薬の出現にもかかわらず、強心薬はその迅速な作用発現、急性脱落における有用性、集中治療および長期心不全治療アルゴリズムにおける確立された役割により、臨床的重要性を保持しています。

ICUや救急部などの急性期では、生命を脅かすほどの心機能低下をきたした患者の安定化に強心剤が不可欠です。慢性期治療では、心房細動の心拍コントロールや駆出率低下型心不全（HFrEF）の入院患者を減らすために、ジゴキシンのような選択的薬剤が使用されます。

新しいドラッグデリバリーモデルとリスク管理戦略は、強心薬の使用をどのように促進しているか？

特にジゴキシンのような古い薬剤では、毒性や治療域の狭さに関する懸念が、歴史的に広範な使用を制限してきたが、投与プロトコール、治療薬物モニタリング（TDM）、個別化治療レジメンの進歩により、安全性と臨床転帰が改善されつつあります。点滴製剤は依然として急性期治療の中心であり、経口製剤は慢性期の維持療法に使用されています。強化されたファーマコビジランス、デジタルモニタリングツール、および患者固有のリスク評価モデルは、臨床医が投与量を最適化し、有害事象を最小限に抑え、より広範な患者集団に安全な使用法を拡大するのに役立っています。

また、臨床試験や観察研究により、強心剤とRAAS阻害薬、SGLT2阻害薬、β遮断薬との併用戦略に対する関心が再び高まっています。これと並行して、心筋効率を改善し、催不整脈リスクプロファイルを低下させた次世代強心薬の研究も進んでおり、現代の心不全治療における収縮力増強薬の役割を再定義することを目指しています。

強心剤の需要が高まっているのはどこで、どの臨床セグメントが利用をリードしているのか？

北米と欧州は、心不全の有病率が高く、ICUのインフラがしっかりしており、急性期治療プロトコルが広く使用されているため、依然として主要市場です。特に米国では、病院での静脈内強心薬の使用が引き続き広がっています。アジア太平洋地域では、特に中国、インド、東南アジアで需要が大きく伸びており、心血管疾患の増加、人口の高齢化、クリティカルケアへのアクセスの拡大が利用拡大を促進しています。

強心剤は、急性心不全、術後心臓補助、進行性心不全など、他の薬物療法では不十分な場合に広く使用されています。使用頻度の高い分野は、循環器科病棟、集中治療室、救急部、心臓手術回復プログラムなどです。さらに、外来心不全クリニックや老人医療センターでは、特定の患者集団の慢性維持療法に低用量レジメンが使用されています。

強心剤市場の世界的成長の原動力は？

世界の強心剤市場は、心不全の罹患率の増加、即効性のある心血管系治療薬に対する需要の増加、急性減圧症における強心薬やレートコントロール薬への臨床的依存の継続に対応して拡大しています。心不全治療がよりプロトコール主導で患者中心に行われるようになる中、強心剤は血行動態を安定させ、患者をより長期的な治療、介入、移植へと橋渡しする上で不可欠なツールであり続けています。

製剤の改良、投与量の柔軟性、安全性モニタリングにおける医薬品の技術革新は臨床的信頼の維持に役立っており、一方、心臓治療への世界のアクセスの拡大は中低所得国に新たな市場を開拓しています。ヘルスケアシステムが心不全患者の増加やリソースの制約と闘う中で、将来を決定づける重大な問題がある：強心剤は、安全性の向上、選択的標的化、併用的統合によって進化することができるのだろうか？

セグメント

薬剤タイプ（ジギタリス配糖体、ホスホジエステラーゼ阻害剤、心保護剤、交感神経刺激剤、その他の薬剤タイプ）、投与経路（経口、非経口）、剤形（錠剤、溶液、その他の剤形）、流通チャネル（病院薬局、小売薬局、オンライン薬局）、用途（心臓外科処置、心房細動、心不全、肺高血圧症、その他の用途）

調査対象企業の例（全34件）

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Fresenius Kabi
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cardiotonic Agents Market to Reach US$3.0 Billion by 2030

The global market for Cardiotonic Agents estimated at US$1.0 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 19.4% over the analysis period 2024-2030. Digitalis Glycosides, one of the segments analyzed in the report, is expected to record a 21.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Phosphodiesterase Inhibitors segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.7 Million While China is Forecast to Grow at 26.5% CAGR

The Cardiotonic Agents market in the U.S. is estimated at US$284.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$720.8 Million by the year 2030 trailing a CAGR of 26.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Global Cardiotonic Agents Market - Key Trends & Drivers Summarized

Why Are Cardiotonic Agents Critical in Managing Acute and Chronic Heart Failure Across Diverse Care Settings?

Cardiotonic agents-primarily used to enhance myocardial contractility-remain a cornerstone in the pharmacologic management of heart failure, cardiogenic shock, and certain arrhythmias. These agents, including digitalis glycosides (e.g., digoxin), phosphodiesterase inhibitors (e.g., milrinone), and adrenergic agonists (e.g., dobutamine), provide vital hemodynamic support in cases of reduced ejection fraction or compromised cardiac output. Despite the emergence of novel heart failure therapies, cardiotonic drugs retain clinical importance due to their rapid onset of action, utility in acute decompensations, and established role in both intensive care and long-term heart failure treatment algorithms.

In acute settings such as ICU and emergency departments, cardiotonic agents are essential for stabilizing patients with life-threatening reductions in cardiac function. In chronic care, select agents like digoxin are used for rate control in atrial fibrillation and to reduce hospitalizations in heart failure with reduced ejection fraction (HFrEF), particularly when guideline-directed therapy is inadequate or contraindicated.

How Are New Drug Delivery Models and Risk Management Strategies Enhancing Use of Cardiotonic Therapies?

While concerns around toxicity and narrow therapeutic windows-particularly with older agents like digoxin-have historically limited broader use, advancements in dosing protocols, therapeutic drug monitoring (TDM), and personalized treatment regimens are improving safety and clinical outcomes. Intravenous formulations remain central to acute management, while oral options are used for maintenance therapy in chronic settings. Enhanced pharmacovigilance, digital monitoring tools, and patient-specific risk assessment models are helping clinicians optimize dosage, minimize adverse events, and extend safe usage across broader patient populations.

Clinical trials and observational studies are also driving renewed interest in combination strategies that pair cardiotonic agents with RAAS inhibitors, SGLT2 inhibitors, and beta blockers. In parallel, research into next-generation inotropes with improved myocardial efficiency and lower pro-arrhythmic risk profiles is progressing, aiming to redefine the role of contractility-enhancing agents in modern heart failure care.

Where Is Demand for Cardiotonic Agents Rising and Which Clinical Segments Are Leading Utilization?

North America and Europe remain key markets due to high heart failure prevalence, strong ICU infrastructure, and extensive use of acute care protocols. The U.S., in particular, continues to see widespread use of IV inotropes in hospital settings. Asia-Pacific is witnessing significant growth in demand, particularly in China, India, and Southeast Asia, where rising cardiovascular disease burden, aging populations, and expanding access to critical care are driving greater utilization.

Cardiotonic agents are used extensively in acute heart failure, post-operative cardiac support, and advanced heart failure where other pharmacologic measures are insufficient. High-use segments include cardiology units, intensive care wards, emergency departments, and cardiac surgery recovery programs. Additionally, outpatient heart failure clinics and geriatric care centers use lower-dose regimens for chronic maintenance in selected patient cohorts.

What Is Fueling the Global Growth of the Cardiotonic Agents Market?

The global cardiotonic agents market is expanding in response to the growing incidence of heart failure, increased demand for rapid-acting cardiovascular drugs, and the continued clinical reliance on inotropes and rate-control medications in acute decompensations. As cardiac care delivery becomes more protocol-driven and patient-centered, cardiotonic agents remain essential tools in stabilizing hemodynamics and bridging patients to longer-term therapies, interventions, or transplantation.

Pharmaceutical innovation in formulation refinement, dosing flexibility, and safety monitoring is helping maintain clinical confidence, while expanding global access to cardiac care is opening new markets in lower- and middle-income countries. As healthcare systems grapple with rising heart failure admissions and resource constraints, a critical question defines the future: Can cardiotonic therapies evolve through improved safety, selective targeting, and combinatory integration-while sustaining their frontline role in life-saving cardiac interventions across care settings?

SCOPE OF STUDY:

The report analyzes the Cardiotonic Agents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types); Administration Route (Oral, Parenteral); Dosage Form (Tablet, Solution, Other Dosage Forms); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Fresenius Kabi
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cardiotonic Agents - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Hospitalization Rates for Heart Failure Reinforce Need for Cardiotonic Pharmacotherapy
  • Intravenous Inotropes Remain Standard in Acute Decompensated Heart Failure Management
  • Global Demand Stabilizes for Digoxin and Dobutamine Amid Entry of Next-Gen Cardiotonic Agents
  • Cardiotonic Therapies Integrated Into ICU Protocols for Short-Term Hemodynamic Support
  • Clinical Trials Evaluate Novel Cardiotonic Compounds With Reduced Pro-Arrhythmic Risk Profiles
  • Aging Populations and Comorbidity Prevalence Sustain Chronic Use of Oral Cardiotonic Medications
  • Hospital Formularies Prioritize Cost-Effective, Rapid-Onset Agents in Emergency Cardiac Care
  • Digital Drug Monitoring Tools Improve Safety in Titration and Therapeutic Drug Monitoring
  • Injectable Cardiotonic Agents Gain Inclusion in Global Critical Care Guidelines
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cardiotonic Agents Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Digitalis Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cardioprotectants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Sympathomimetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Cardiac Surgical Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Heart Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Pulmonary Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• JAPAN
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Japan 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CHINA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 104: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: China 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: China Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: China 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 116: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: China 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• EUROPE
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 128: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• FRANCE
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 137: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 140: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: France 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 143: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: France Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: France 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: France Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: France 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 149: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: France 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• GERMANY
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 152: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Germany Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Germany 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Germany 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 158: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Germany Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Germany 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Germany Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Germany 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Germany 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 167: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Italy Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Italy 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Italy 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 173: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Italy Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Italy 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Italy Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Italy 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Italy 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 182: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: UK Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: UK 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 185: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: UK 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 188: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UK Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: UK 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 191: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UK Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: UK 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 194: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: UK 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 197: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Spain Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Spain 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Spain 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 203: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Spain Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Spain 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Spain Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Spain 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Spain 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 212: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Russia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Russia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Russia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 218: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Russia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Russia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Russia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Russia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Russia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Asia-Pacific Historic Review for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 260: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Australia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Australia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Australia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 266: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Australia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Australia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Australia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Australia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Australia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• INDIA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 275: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: India Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: India 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: India 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 281: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: India Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: India 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: India Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: India 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 287: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: India 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 290: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: South Korea Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: South Korea 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: South Korea 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 296: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: South Korea Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: South Korea 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: South Korea Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: South Korea 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: South Korea 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 320: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Latin America Historic Review for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Latin America 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 329: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 338: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Argentina Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Argentina 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Argentina 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 344: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Argentina Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Argentina 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 347: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Argentina Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Argentina 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Argentina 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 353: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Brazil Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Brazil 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Brazil 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 359: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Brazil Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Brazil 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 362: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Brazil Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Brazil 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Brazil 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 368: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Mexico Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Mexico 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Mexico 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 374: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Mexico Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Mexico 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 377: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Mexico Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Mexico 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Mexico 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 398: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 399: Middle East Historic Review for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Middle East 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 407: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 416: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Iran Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 418: Iran 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 421: Iran 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 422: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Iran Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 424: Iran 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 425: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Iran Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 427: Iran 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 430: Iran 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 431: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Israel Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 433: Israel 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 436: Israel 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 437: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Israel Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 439: Israel 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 440: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Israel Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 442: Israel 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 445: Israel 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Saudi Arabia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 448: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Saudi Arabia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 454: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Saudi Arabia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 457: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 461: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 462: UAE Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 463: UAE 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 466: UAE 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 467: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 468: UAE Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 469: UAE 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 470: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 471: UAE Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 472: UAE 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 475: UAE 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Rest of Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 478: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Rest of Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 484: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Rest of Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 487: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AFRICA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 491: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Africa Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 493: Africa 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 496: Africa 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 497: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Africa Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 499: Africa 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 500: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Africa Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 502: Africa 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 505: Africa 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030

IV. COMPETITION